Tong Ren Tang Technology (01666) proposes to appoint Zhang Yi as a non-executive director
Tong Ren Tang Technology (01666) announced that since the term of the 8th board of directors will expire at the end of the annual general meeting of shareholders, Dong...
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
Tong Ren Tang Chinese Medicine Appoints CEO
Tong Ren Tang Chinese Medicine (HKG:3613) has appointed Wang Chi as its new chief executive officer, effective May 10, according to a filing with Hong Kong Exchange last Friday. The acting CEO Chen Fe
Tong Ren Tang Registers Danggui Buxue Granules in Hong Kong
Beijing Tong Ren Tang Group (SHA:600085) received the certificate of registration from Hong Kong's Chinese Medicine Council for Danggui Buxue granules, according to the company's filing on the Shangha
Beijing Tong Ren Tang Gets Nod to Sell Fever Drug in Hong Kong
Beijing Tong Ren Tang Chinese Medicine (HKG:3613), a unit of Tong Ren Tang Technologies (HKG:1666), has obtained approval to sell its drug Danggui Buxue Keli in Hong Kong, a Tuesday filing by the latt
Tong Ren Tang's Q1 Profit Jumps 10%, Revenue Rises 2%
Beijing Tong Ren Tang Group's (SHA:600085) attributable net profit edged up 10% year over year in the first quarter to 575.9 million yuan from 523.4 million yuan a year earlier, the company said in a
同仁堂科技:年報2023
Express News | The mercury content in Beijing Tongrentang was questioned, and customer service said the production met national standards
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Express News | Guojin Securities: Focus on opportunities such as in vitro diagnostic collection clean-up and proprietary Chinese medicine collection
Express News | Capital Securities: The high dividend rate in the Chinese medicine industry is stable and sustainable
Stable sector+product space, Tongrentang Technology (01666.HK)'s dual market potential
As we all know, in the Hong Kong stock market, Chinese medicine stocks have been undervalued for a long time. Judging from the net market ratio, the net market ratio of the entire traditional Chinese medicine concept is less than 1 times. A large part of the reason behind this is that investors in the Hong Kong stock market, especially foreign investors, have long had no understanding of traditional Chinese medicine or traditional Chinese medicine, and even misunderstood the introduction of animals and plants into medicine.
Beijing Tong Ren Tang Chinese Medicine CEO Steps Down; Acting CEO Appointed
Beijing Tong Ren Tang Chinese Medicine (HKG:3613) said Yu Jin resigned as the company's chief executive officer due to personal endeavors, according to a Thursday Hong Kong bourse filing. Chen Fei wil
Tong Ren Tang Technology (01666.HK): Revenue is in line with expectations, increased layout of core products
Revenue for 2023 is in line with our expectations, and net profit is slightly lower than our expectations Tongrentang Technology announced 2023 results: revenue increased 13.04% year-on-year to RMB 6.78 billion, in line with our expectations; net profit to mother 5.
Tong Ren Tang Technology (1666.HK): Large variety strategy consolidates basic market technology parent company to achieve steady growth
Core view The company's 2023 results announcement showed that revenue and net profit attributable to mother increased by 13.04% and 1.25%, respectively, year-on-year, in line with forecast expectations. Revenue structure is divided, parent company and domestic subsidiary are growing well, overseas subsidiaries are short
Tong Ren Tang Technologies Co. Ltd. Non-GAAP EPS of C$0.43, Revenue of C$23.89M
Tung Yan Tong Technology Announces 2023 Annual Results
BEIJING, MARCH 25, 2024 /NEWS MEDIA/ -- BEIJING TONGRENTANG TECHNOLOGY DEVELOPMENT CO., LTD. (“TONG YANTANG TECHNOLOGY” OR THE “GROUP”, 1666.HK) IS PLEASED TO ANNOUNCE THE GROUP'S AUDITED CONSOLIDATED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2013. In 2013, the Group achieved revenues of RMB67.7 billion, an increase of 13.04% year-on-year; achieved net net income of RMB5.9 billion, an increase of 1.25% year-on-year; in terms of products, the Group sold 62 products of more than RMB 500 million and sales of more than RMB 1 billion.
Good sector+performance catalyst, explaining in detail the differences in Tongrentang Technology (01666.HK)'s dual market expectations
Under a series of favorable policies, Tong Ren Tang Technology, as a highly recognizable and even scarce enterprise in the Hong Kong stock market, will benefit.
Featured announcements | Meituan Q4 revenue increased 22.6% year on year, adjusted net profit increased more than 4 times; Evergrande withdraws overseas debt restructuring application
Zijin Mining's net profit in 2023 was 21.119 billion yuan, up 5.38% year on year; Zhou Shengsheng's profit increased by about 124% last year; BAIC's annual net profit fell nearly 30%.
Tongrentang Technology (01666.HK)'s 2023 revenue of 6.773 billion yuan increased 13.04% year-on-year
Gelonghui, March 22丨Tong Ren Tang Technology (01666.HK) announced that for the year ended December 31, 2023, the Group's revenue was RMB 6.773 billion, up 13.04% year on year; net profit attributable to company owners was RMB 590 million, up 1.25% over the same period last year; earnings per share was RMB 0.46 (2022: RMB 0.46); and dividend per share was RMB 0.18 (2022: RMB 0.16). Throughout the year, the Group is committed to adapting to the new normal in the traditional Chinese medicine industry, continuing to focus on core competitive advantages, and advancing
No Data